You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.


Go back

BEXSERO: Help protect the broadest population[1]

BEXSERO is indicated for active immunisation of individuals from 2 months of age and older against invasive meningococcal disease caused by Neisseria meningitidis group B. [1]

MenB awareness: Did you know?

2 of 3 parents are unaware that there is a separate vaccine against MenB.
Some parents believe that their child may have already been protected from MenB with just a meningococcal conjugate (MenACWY) vaccine.[5],ᵃ


ᵃN=3600 parents and legal guardians from 8 countries (Australia, Brazil, Germany, Greece, Italy, Spain, UK, and USA) participated in a survey.

Common questions and answers with BEXSERO

When your patients and their parents come to you with these common questions, BEXSERO may be the answer.


  1. Bexsero Prescribing Information GDS 10/ Date: 09 November 2018.
  2. Pfizer Ltd. Trumenba Annex I; Summary of Product Characteristics EMA; May 2018. 
  3. Deceuninck G, Lefebvre B, Tsang R, Betala-Belinga JF, De Serres G, De Wals P. Impact of a mass vaccination campaign against Serogroup B meningococcal disease in the Saguenay-Lac-Saint-Jean region of Quebec four years after its launch. Vaccine. 2019;37(31):4243–4245. 
  4. Ladhani SN, Andrews N, Parikh SR, et al. Vaccination of infants with meningococcal group B vaccine (4CMenB) in England. N Engl J Med. 2020;382(4):309–317.
  5. GSK Data on file: 2019N405209_01. 
  6. European Centre for Disease Prevention and Control. Invasive meningococcal disease: In: ECDC. Annual epidemiological report for 2017. Stockholm: ECDC; 2017. Accessed September 2019.

All mentioned products are registered in Saudi Arabia. This page may contain promotional content. For full prescribing information or adverse events reporting, please click on the relevant button in the header or footer of this page

Trade marks are owned by or licensed to the GSK group of companies.
©2020 GSK group of companies or its licensor.

PM-SA-BEX-WCNT-200002 Date of preparation: September 2020